Does sngx stock pay a dividend?
The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. More... SNGX does not currently pay a dividend.
Who buys Soligenix (sngx)?
SNGX stock was purchased by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Two Sigma Securities LLC, Geode Capital Management LLC, and Millennium Management LLC. Company insiders that have bought Soligenix stock in the last two years include Christopher J Schaber, Jerome B Zeldis, and Jonathan L Guarino.
What is the goal of the sngx study?
The goal is to gather enough data during trials to make that happen. ... SNGX: Durable Immunity for RiVax® Vaccine…
Is Sngx a good buy?
Soligenix Inc (NASDAQ:SNGX) The 1 analysts offering 12-month price forecasts for Soligenix Inc have a median target of 3.75, with a high estimate of 3.75 and a low estimate of 3.75. The median estimate represents a +346.43% increase from the last price of 0.84.
Is soligenix a good investment?
Soligenix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Should I buy or sell Soligenix stock right now?
1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Soligenix in the last year. There are currently 1 buy rating for...
What is Soligenix's stock price forecast for 2022?
1 equities research analysts have issued 1-year price objectives for Soligenix's shares. Their forecasts range from $3.75 to $3.75. On average, the...
How has Soligenix's stock performed in 2022?
Soligenix's stock was trading at $0.66 at the beginning of the year. Since then, SNGX shares have decreased by 9.1% and is now trading at $0.60. V...
Are investors shorting Soligenix?
Soligenix saw a increase in short interest in May. As of May 31st, there was short interest totaling 667,000 shares, an increase of 36.5% from the...
When is Soligenix's next earnings date?
Soligenix is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for Soligenix .
How were Soligenix's earnings last quarter?
Soligenix, Inc. (NASDAQ:SNGX) posted its quarterly earnings data on Tuesday, March, 29th. The biopharmaceutical company reported ($0.11) earnings p...
Who are Soligenix's key executives?
Soligenix's management team includes the following people: Dr. Christopher J. Schaber Ph.D. , Chairman, CEO & Pres (Age 56, Pay $611.46k) ( Link...
Who are some of Soligenix's key competitors?
Some companies that are related to Soligenix include Magenta Therapeutics (MGTA) , GT Biopharma (GTBP) , Ardelyx (ARDX) , TherapeuticsMD (TXMD)...
What other stocks do shareholders of Soligenix own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV) , T2...
What is the SNGX symbol?
How much does Soligenix make?
Soligenix trades on the NASDAQ under the ticker symbol "SNGX."
What is the P/E ratio of Soligenix?
How much money does Soligenix make? Soligenix has a market capitalization of $38.66 million and generates $2.36 million in revenue each year. The biopharmaceutical company earns $-17,690,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis.
What is Soligenix?
The P/E ratio of Soligenix is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Is Soligenix a hold?
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.
Does Soligenix pay dividends?
Wall Street analysts have given Soligenix a "Hold" rating, but there may be better buying opportunities in the stock market . Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Soligenix wasn't one of them.
